regardless of positive clinical evidence, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering substantial resistance from PBMs. Such organizations are often building barriers to coverage, including high expense criteria and PA that restrict consumer opportunity. Market indicate that these ac